Eli Lilly Says Higher Trulicity Doses Reduced A1C, Weight in People with Type 2 Diabetes
May 08 2020 - 3:45PM
Dow Jones News
By Michael Dabaie
Eli Lilly & Co. said new 36-week data showed higher
investigational doses of Trulicity were well-tolerated and led to
A1C reductions up to 1.9% and weight reductions up to 10.4 pounds
in people with type 2 diabetes.
The results from Lilly's Award-11 trial, which evaluated higher
investigational doses of Trulicity, 3 mg and 4.5 mg, compared to
Trulicity 1.5 mg, were published in the Journal of the Endocrine
Society.
The trial "confirmed our expectations that a higher
investigational dose of Trulicity would lead to superior blood
glucose and weight reductions in people with type 2 diabetes
compared to Trulicity 1.5 mg," said Juan Pablo Frias, medical
director and principal investigator at National Research
Institute.
Results at 52 weeks were consistent with the 36-week results and
further details will be disclosed at a later date, Lilly said. The
Award-11 results have been submitted to regulatory authorities in
the U.S. and Europe for review.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
May 08, 2020 15:30 ET (19:30 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Apr 2024 to May 2024
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From May 2023 to May 2024